FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590315902> ?p ?o ?g. }

• W2590315902 endingPage "537" @default.
• W2590315902 startingPage "528" @default.
• W2590315902 abstract "Background Escherichia coli infections are increasing worldwide in community and hospital settings. The E coli O-antigen is a promising vaccine target. We aimed to assess the safety and immunogenicity of a bioconjugate vaccine containing the O-antigens of four E coli serotypes (ExPEC4V). Methods In this multicentre phase 1b, first-in-human, single-blind, placebo-controlled trial, we randomly assigned (1:1) healthy adult women with a history of recurrent urinary tract infection (UTI) to receive a single injection of either intramuscular ExPEC4V or placebo. The primary outcome was the incidence of adverse events among vaccine and placebo recipients throughout the study. Secondary outcomes included immunogenicity and antibody functionality, and the incidence of UTIs caused by E coli vaccine serotypes in each group. This study is registered with ClinicalTrials.gov, number NCT02289794. Findings Between Jan 20, 2014, and Aug 27, 2014, 93 women received target-dose ExPEC4V and 95 received placebo. The vaccine was well tolerated: no vaccine-related serious adverse events occurred. Overall, 56 (60%) target-dose vaccines and 47 (49%) placebo recipients experienced at least one adverse event that was possibly, probably, or certainly related to injection. Vaccination induced significant IgG responses for all serotypes: at day 30 compared with baseline, O1A titres were 4·6 times higher, O2 titres were 9·4 times higher, O6A titres were 4·9 times higher, and O25B titres were 5·9 times higher (overall p<0·0001). Immune responses persisted at 270 days but were lower than those at 30 days. Opsonophagocytic killing activity showed antibody functionality. No reduction in the incidence of UTIs with 103 or more colony-forming units per mL of vaccine-serotype E coli was noted in the vaccine compared with the placebo group (0·149 mean episodes vs 0·146 mean episodes; p=0·522). In post-hoc exploratory analyses of UTIs with higher bacterial counts (≥105 colony-forming units per mL), the number of vaccine serotype UTIs did not differ significantly between groups (0·046 mean episodes in the vaccine group vs 0·110 mean episodes in the placebo group; p=0·074). However, significantly fewer UTIs caused by E coli of any serotype were noted in the vaccine group compared with the placebo group (0·207 mean episodes vs 0·463 mean episodes; p=0·002). Interpretation This tetravalent E coli bioconjugate vaccine candidate was well tolerated and elicited functional antibody responses against all vaccine serotypes. Phase 2 studies have been initiated to confirm these findings. Funding GlycoVaxyn, Janssen Vaccines." @default.
• W2590315902 created "2017-03-03" @default.
• W2590315902 creator A5002201239 @default.
• W2590315902 creator A5003503698 @default.
• W2590315902 creator A5012388611 @default.
• W2590315902 creator A5016203888 @default.
• W2590315902 creator A5019440562 @default.
• W2590315902 creator A5033396672 @default.
• W2590315902 creator A5037333161 @default.
• W2590315902 creator A5037469107 @default.
• W2590315902 creator A5037512746 @default.
• W2590315902 creator A5038094499 @default.
• W2590315902 creator A5052440696 @default.
• W2590315902 creator A5061015928 @default.
• W2590315902 creator A5061675261 @default.
• W2590315902 creator A5063381434 @default.
• W2590315902 creator A5069262777 @default.
• W2590315902 creator A5070030726 @default.
• W2590315902 creator A5071344141 @default.
• W2590315902 creator A5075181360 @default.
• W2590315902 creator A5077971584 @default.
• W2590315902 creator A5078620520 @default.
• W2590315902 creator A5079419922 @default.
• W2590315902 creator A5083417214 @default.
• W2590315902 creator A5084792815 @default.
• W2590315902 creator A5085844112 @default.
• W2590315902 creator A5085949901 @default.
• W2590315902 creator A5090484512 @default.
• W2590315902 date "2017-05-01" @default.
• W2590315902 modified "2023-10-13" @default.
• W2590315902 title "Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial" @default.
• W2590315902 cites W1845923557 @default.
• W2590315902 cites W1971518631 @default.
• W2590315902 cites W1979375416 @default.
• W2590315902 cites W1992458615 @default.
• W2590315902 cites W2020963636 @default.
• W2590315902 cites W2024620984 @default.
• W2590315902 cites W2031240692 @default.
• W2590315902 cites W2039094592 @default.
• W2590315902 cites W2070920909 @default.
• W2590315902 cites W2078645039 @default.
• W2590315902 cites W2078703243 @default.
• W2590315902 cites W2090499893 @default.
• W2590315902 cites W2094204413 @default.
• W2590315902 cites W2097822636 @default.
• W2590315902 cites W2098716491 @default.
• W2590315902 cites W2107665084 @default.
• W2590315902 cites W2119495692 @default.
• W2590315902 cites W2119506596 @default.
• W2590315902 cites W2120750073 @default.
• W2590315902 cites W2129842338 @default.
• W2590315902 cites W2140019337 @default.
• W2590315902 cites W2143539359 @default.
• W2590315902 cites W2161171034 @default.
• W2590315902 cites W2237653881 @default.
• W2590315902 cites W2243816940 @default.
• W2590315902 cites W2465657035 @default.
• W2590315902 cites W2515325379 @default.
• W2590315902 cites W2517496869 @default.
• W2590315902 cites W4230357700 @default.
• W2590315902 doi "https://doi.org/10.1016/s1473-3099(17)30108-1" @default.
• W2590315902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28238601" @default.
• W2590315902 hasPublicationYear "2017" @default.
• W2590315902 type Work @default.
• W2590315902 sameAs 2590315902 @default.
• W2590315902 citedByCount "141" @default.
• W2590315902 countsByYear W25903159022017 @default.
• W2590315902 countsByYear W25903159022018 @default.
• W2590315902 countsByYear W25903159022019 @default.
• W2590315902 countsByYear W25903159022020 @default.
• W2590315902 countsByYear W25903159022021 @default.
• W2590315902 countsByYear W25903159022022 @default.
• W2590315902 countsByYear W25903159022023 @default.
• W2590315902 crossrefType "journal-article" @default.
• W2590315902 hasAuthorship W2590315902A5002201239 @default.
• W2590315902 hasAuthorship W2590315902A5003503698 @default.
• W2590315902 hasAuthorship W2590315902A5012388611 @default.
• W2590315902 hasAuthorship W2590315902A5016203888 @default.
• W2590315902 hasAuthorship W2590315902A5019440562 @default.
• W2590315902 hasAuthorship W2590315902A5033396672 @default.
• W2590315902 hasAuthorship W2590315902A5037333161 @default.
• W2590315902 hasAuthorship W2590315902A5037469107 @default.
• W2590315902 hasAuthorship W2590315902A5037512746 @default.
• W2590315902 hasAuthorship W2590315902A5038094499 @default.
• W2590315902 hasAuthorship W2590315902A5052440696 @default.
• W2590315902 hasAuthorship W2590315902A5061015928 @default.
• W2590315902 hasAuthorship W2590315902A5061675261 @default.
• W2590315902 hasAuthorship W2590315902A5063381434 @default.
• W2590315902 hasAuthorship W2590315902A5069262777 @default.
• W2590315902 hasAuthorship W2590315902A5070030726 @default.
• W2590315902 hasAuthorship W2590315902A5071344141 @default.
• W2590315902 hasAuthorship W2590315902A5075181360 @default.
• W2590315902 hasAuthorship W2590315902A5077971584 @default.
• W2590315902 hasAuthorship W2590315902A5078620520 @default.
• W2590315902 hasAuthorship W2590315902A5079419922 @default.
• W2590315902 hasAuthorship W2590315902A5083417214 @default.
• W2590315902 hasAuthorship W2590315902A5084792815 @default.
• W2590315902 hasAuthorship W2590315902A5085844112 @default.

• next